News
The FDA's breakthrough devices program is intended to provide patients and health care providers with timely access to ...
Q1 2025 Management View CEO Eric Dube reported strong progress for the quarter, highlighting FILSPARI's foundational role in treating IgA nephropathy (IgAN). Net sales of FILSPARI increased 13% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback